TA 5538

Drug Profile

TA 5538

Alternative Names: TA-5538

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tanabe Seiyaku
  • Class Urologics
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Overactive bladder

Most Recent Events

  • 12 May 2010 Discontinued - Phase-II for Overactive bladder in Europe (unspecified route)
  • 12 May 2010 Discontinued - Phase-II for Overactive bladder in Japan (unspecified route)
  • 01 Oct 2007 Tanabe Seiyaku Co. Ltd merged with Mitsubishi Pharma Corporation to form Mitsubishi Tanabe Pharma Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top